OMALIZUMAB

omalizumab 300 mg/2 mL injection, 2 mL pen device

OMALIZUMAB (14913X)

omalizumab 300 mg/2 mL injection, 2 mL pen device
14913X
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Severe chronic spontaneous urticaria
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $418.14 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Xolair